Earnings ·
Humacyte reports Q3 Symvess sales of $1.0 million, a 151% increase from the prior quarter
HUMAWHumacyte, Inc.
Humacyte reported third-quarter commercial sales of $1.0 million for its Symvess product, representing a 151% sequential increase and doubling second-quarter results. The company expanded hospital adoption to 49 facilities and anticipates Q4 sales to at least double the previous quarter's run rate. Financially, Humacyte posted a net loss of $15.5 million for the period, driven by higher cost of goods sold and research expenses, though cash reserves stood at $64.9 million. The company also initiated a first-in-human Phase 2a study for its CTEV product in coronary artery bypass grafting and plans to file a supplemental Biologics License Application with the FDA for ATEV dialysis access use in November 2026. Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues.